“Glucagon-like Peptide-1 Receptor Agonist Treatment in Type 1 Diabetes: A Review of Current Evidence and Rationale for Use” (2023) Canadian Diabetes & Endocrinology Today, 1(3), pp. 21–26. doi:10.58931/cdet.2023.1318.